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Objectives: The epithelial-mesenchymal-transition (EMT) is an important step in the invasion and metastasis of
cancer. A critical molecular feature of this process is the downregulation of the E-cadherin expression, which is
primarily controlled by Snail-related zinc-finger transcription factors. The aim of this study was to evaluate the prognostic
impact of the expression of EMT-related proteins (E-cadherin and Snail) in patients with ovarian cancer.
Methods: An immunohistochemical analysis was conducted using tissue microarray samples of 174 primary tumors and
34 metastases of ovarian carcinoma, and the relationships between the protein expression, clinicopathological features
and outcomes were investigated.
Results: A reduced E-cadherin expression was observed in 36.8% of the primary tumors and 30.4%, 35.7%, 37.7% and
52.7% of the stage I, II, III and IV tumors, respectively. The nuclear expression of Snail was positive in 33.9% of the primary
tumors. The rate of an EMT-positive status, as represented by both a reduced E-cadherin expression and a nuclear
expression of Snail, was significantly higher in the patients with peritoneal dissemination than in those without
(p < 0.05). The EMT status was significantly associated with both the progression-free survival and overall survival
(p <0.01). A multivariate analysis showed an EMT-positive status to be a significant predictor of both the progression-free
survival (p < 0.05) and overall survival (P < 0.01).
Conclusions: These data indicate that the EMT status is significantly associated with peritoneal metastasis and both the
progression-free survival and overall survival in patients with ovarian cancer. Therefore, clarifying and controlling EMT
signaling is a promising approach to molecular targeted therapy for ovarian cancer.
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Ovarian cancer is the most frequent cause of cancer-related
death among all gynecological cancers. Approximately 70%
of patients with ovarian cancer are diagnosed at an ad-
vanced stage [1]. The degree of peritoneal dissemination is
related to a poor prognosis in patients with advanced-stage
ovarian cancer. The molecular mechanisms allowing ovar-
ian cancer cells to detach from the primary tumor, invade
the peritoneal surface and regrow at this site are not yet* Correspondence: y-terai@poh.osaka-med.ac.jp
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unless otherwise stated.well understood. Therefore, obtaining a better under-
standing of the molecular events that contribute to
tumor invasion and metastasis is crucial for developing
novel treatment strategies for ovarian cancer.
The epithelial-mesenchymal-transition (EMT), referring
to changes in the cell phenotype from an epithelial morph-
ology to a mesenchymal morphology, is an important step
in the invasion and metastasis of cancer. The EMT plays
key roles in embryonic development and its importance in
the pathogenesis of cancer and other human diseases is be-
ing increasingly recognized [2-5]. The EMT is associated
with the progressive redistribution or downregulation ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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adherens junction proteins, such as E-cadherin and
cytokeratin, and the novel expression of mesenchymal
molecules, such as vimentin and N-cadherin [6,7]. Key
factors regulating the EMT program include Snail-related
zinc-finger transcription factors (Snail or Slug) [8,9]. Snail
was first described in Drosophila melanogaster as a regula-
tor of mesoderm formation [10] and has been suggested to
be involved in the acquisition of resistance to apoptosis,
thereby promoting tumor survival [11-13]. Therefore, Snail
is thought to be involved in the invasion and metastasis of
cancer cells by stimulating the EMT.
Alternations in cellular adhesion molecules, such as
E-cadherin, are important for the development of an
invasive and metastatic capacity in human cancer cells
[14,15]. A decreased E-cadherin expression is related to
a more infiltrative growth pattern in a variety of cancers
[16-18] and is an independent prognostic factor of endo-
metrial cancer [19,20]. The loss of the E-cadherin ex-
pression is a hallmark of the EMT. Other transcription
factors (Zeb1/dEF-1, Zeb2/SIP1 and E12/E47) have also
been shown to repress the activity of E-cadherin [8,21,22].
Recent work in hepatocellular carcinoma, oral squamous
cell carcinoma and breast cancer [23-26] suggests that the
transcription factors Snail is an important predictor of the
invasiveness of E-cadherin, a component of adherens junc-
tions [27]. Indeed, Snail has been identified to be a powerful
E-cadherin inhibitor in both normal tissues and tumors
[23,27,28]. Moreover, Snail plays a key role in the devel-
opment of gynecologic malignancies and has an impact
on the prognosis [29-32]. In addition, we previously
demonstrated the prognostic impact of the expression
of EMT-related proteins (E-cadherin, Snails) in patients
with endometrial cancer [33]. However, no studies have
thus far clarified the prognostic impact of the EMT-related
protein expression in patients with ovarian cancer. There-
fore, the current study aimed to assess whether the Snail
expression is related to E-cadherin suppression in patients
with ovarian cancer and investigate the clinical relevance
and prognostic impact of the EMT status, based on both a
reduced E-cadherin expression and the presence of a nu-
clear Snail expression in this type of tumor.
Materials and methods
Tissue samples
Tissue samples and relevant clinical data were obtained
from 174 Japanese patients who underwent surgical resec-
tion for primary epithelial ovarian cancer at Osaka Medical
College. The Institutional Review Board of Osaka Medical
College approved this study, and informed consent was ob-
tained from all patients. The specimens were fixed in 10%
formalin and embedded in paraffin. Serial sections cut
from the paraffin-embedded blocks were used for rou-
tine histopathology. Four-μm-thick sections were cutfrom the tissue microarray block and immunohisto-
chemically analyzed for the expression of E-cadherin
and Snail. Metastases were found in the lymph nodes
(n = 13) and peritoneal region (n = 34). The specimens
of the primary tumor and corresponding metastases
were also analyzed.Immunohistochemistry
Four-μm-thick paraffin-embedded tissue sections of
tumor samples were stained immunohistochemically.
The expression levels of E-cadherin and Snail were ana-
lyzed as follows. Briefly, deparaffinized and rehydrated
sections were autoclaved in 0.01 mol/l of citrate buffer,
pH 6.0 for 15 minutes at 121°C for antigen retrieval. The
endogenous peroxidase activity was blocked with 0.3%
solution hydrogen peroxide in methanol for 30 minutes.
The tumor sections were incubated at 4°C for 12 hours
with the E-cadherin-specific antibody, E-cadherin (24E10),
at a 1:50 dilution (Cell Signaling Technology) and Snail
antibody (N-term D24), at a 1:100 dilution (ABGENT).
Next, the sections were washed with 1× phosphate-
buffered saline (PBS) and incubated with Histofine
simple stain MAX PO (multi) (Nichirei) for 30 minutes
at room temperature. Finally, after washing with 1×
PBS, signals were visualized via incubation with H2O2/
diaminobenzidine substrate solution for five minutes.
The sections were counterstained with hematoxylin
prior to dehydration and mounting. The evaluation of
the immunohistochemical data was performed by two
independent pathologists blinded to the patients’ clini-
copathological data.Immunohistochemical evaluations
The expression levels of E-cadherin and Snail were assessed
using a semiquantitative system, ranging from 0, 1+, 2+ to
3+, defined as described by Blechscmidt K. et al. Briefly, the
E-cadherin expression was scored as follows: 0 (no stain-
ing), 1+ (low-intensity immunoreactivity of more than 10%
of the tumor cells), 2+ (medium-intensity immunoreactivity
of more than 10% of the tumor cells) or 3+ (high-intensity
immunoreactivity of more than 10% of the tumor cells).
We classified these data into two groups: those indicating a
preserved E-cadherin expression (3+) and those indicating
a reduced E-cadherin expression (0, 1+, 2+). The Snail ex-
pression was evaluated as being positive only when nuclear
staining was detectable, as follows: 0 (no staining), 1+ (im-
munoreactivity of more than 1% of the tumor cells), 2+
(immunoreactivity of more than 2-5% of the tumor cells) or
3+ (immunoreactivity of more than 5% of the tumor cells).
The data were also classified into two groups: those indicat-
ing negative (0) and positive (1+, 2+, 3+) results. Scoring
was performed three times per slide for three distinct fields,
and the three scores were averaged.
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The statistical analyses were performed using the JMP®9
software program (SAS Institute Inc., Cary, NC, USA).
The Χ2 test and Fisher’s exact probability test were used
to evaluate correlations between the immunohistochem-
ical and clinical data. The analyzed clinical outcomes in-
cluded the progression-free survival (PFS) and overall
survival (OS). Progression-free survival was defined as
the time from the first day of treatment until the first of
either death from any cause or disease progression. Overall
survival was defined as the time from the first day of treat-
ment to death from any cause. Univariate and multivariate
analyses of the progression-free and overall survival were
conducted according to the Kaplan-Meier method using
the log-rank test and a Cox proportional hazards model,
respectively. Differences with a P-value of less than 0.05
were considered to be statistically significant.
Results
E-cadherin and Snail expression levels
We investigated data regarding the patients’ age, hist-
ology, FIGO (International Federation of Gynecology
and Obstetrics) stage, peritoneal cytology, lymph node
metastasis, peritoneal metastasis and outcomes. The 174
epithelial ovarian cancers included 48 serous adenocarcin-
omas, 21 mucinous adenocarcinomas, 32 endometrioidFigure 1 Representative example of sequential sections immunohistoche
adenocarcinoma G1 (A) and clear cell carcinoma (B) (A, B 40× original ma
indicated in the Materials and methods, while the Snail expression was d
3+, as indicated in the Materials and methods. (B) The E-cadherin expre
while the Snail expression was detected primarily in the cytoplasm of th
the Materials and methods. The scale bars represent 100 μm.adenocarcinomas, 32 clear cell adenocarcinomas, 26 SSPCs
(serous surface papillary carcinomas) and 15 others. Of the
174 investigated patients, 56, 14, 85 and 19 were catego-
rized as having Stage I, II, III and IV disease, respectively.
Representative examples of immunohistochemically stained
sections are shown in Figure 1. The results are shown in
Table 1. A reduced E-cadherin expression was observed in
36.8% of the primary tumors. The rates of a reduced
E-cadherin expression among the patients with clear cell
adenocarcinoma and SSPC were significantly higher than
those observed in those with other histological subtypes
(p < 0.01). In the analysis of the FIGO stage, the rate of a re-
duced E-cadherin expression was 30.4%, 35.7%, 37.7% and
52.7% among the patients with Stage I, II, III and IV dis-
ease, respectively. There were no significant associations
between the rate of a reduced E-cadherin expression and
the FIGO stage or peritoneal cytology. However, the rate of
a reduced E-cadherin exhibited a tendency to be higher in
the patients with peritoneal metastasis than in those with-
out (p = 0.09).
The Snail expression was primarily observed in the
cytoplasm; therefore, if nuclear Snail staining was de-
tected, we classified the sample as positive. A nuclear ex-
pression of Snail was detected in 33.9% of the primary
tumors. The rate of a nuclear expression of Snail was
significantly higher among the patients with mucinousmically stained with Snail and E-cadherin in ovarian endometrioid
gnification). (A) The E-cadherin expression was scored as 0, as
etected primarily in the nucleus of the tumor cells and scored as
ssion was scored as 3+, as indicated in the Materials and methods,
e tumor cells, not in the nucleus, and scored as 0, as indicated in
Table 1 Results of immunohistochemistry
Variables E-cadherin Snail (nuclear)
Preserved (%) Reduced (%) p-value Negative (%) Positive (%) p-value
Age 0.80 0.14
< 50 29 (61.7) 18 (38.3) 27 (57.4) 20 (42.6)
≥ 50 81 (63.8) 46 (36.2) 88 (69.3) 39 (30.7)
Histology <0.01 <0.05
Serous 30 (62.5) 18 (37.5) 34 (70.8) 14 (29.2)
Mucinous 17 (81.0) 4 (19.0) 7 (33.3) 14 (66.7)
Clear 16 (50.0) 16 (50.0) 23 (71.9) 9 (28.1)
Endometrioid 27 (84.4) 5 (15.6) 22 (68.8) 10 (31.2)
SSPC 13 (50.0) 13 (50.0) 17 (65.4) 9 (34.6)
Others 7 (46.7) 8 (53.3) 12 (80.0) 3 (20.0)
FIGO stage 0.39 0.68
I 39 (69.6) 17 (30.4) 40 (71.4) 16 (28.6)
II 9 (64.3) 5 (35.7) 10 (71.4) 4 (28.6)
III 53 (62.3) 32 (37.7) 53 (62.3) 32 (37.7)
IV 9 (47.3) 10 (52.7) 12 (63.2) 7 (36.8)
Peritoneal cytology 0.91 0.18
Positive 85 (63.4) 49 (36.6) 85 (63.4) 49(36.6)
Negative 25 (62.5) 15 (37.5) 30 (75.0) 10 (25.0)
Lymph node metastasis 0.25 0.14
Positive 22 (66.7) 11 (33.3) 19 (57.6) 14 (42.4)
Negative 60 (67.4) 29 (32.6) 65 (73.0) 24 (27.0)
Nx* 28 (53.8) 24 (46.2) 31 (59.6) 21 (40.4)
Peritoneal dissemination 0.09 0.10
Positive 54 (57.4) 40 (42.6) 57 (60.6) 37 (39.4)
Negative 56 (70.0) 24 (30.0) 58 (72.5) 22 (27.5)
Recurrence <0.01 0.73
− 30 (44.1) 38 (55.9) 46 (67.6) 22 (32.4)
+ 80 (75.5) 26 (24.5) 69 (65.1) 37 (34.9)
End stage <0.05 0.09
Alive 79 (68.7) 36 (31.3) 81 (70.4) 34 (29.6)
Dead 31 (52.5) 28 (47.5) 34 (57.6) 25 (42.4)
*Nx: no lymphadenectomy.
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histological subtypes (p < 0.05). In the analysis of the
FIGO stage, the rate of a nuclear expression of Snail was
28.6%, 28.6%, 37.7% and 36.8% among the patients with
Stage I, II, III and IV disease, respectively. There were no
significant associations between the rate of a nuclear ex-
pression of Snail and the FIGO stage, peritoneal cytology or
presence of peritoneal or lymph node metastasis.
EMT status
Snail has been identified to be a powerful E-cadherin in-
hibitor in both normal tissues and tumors [23,27,28].
Accordingly, the EMT status was represented by both areduced E-cadherin expression and the presence of a nu-
clear Snail expression. The results are shown in Table 2.
The rate of an EMT-positive status was 12.5%, 28.6%,
20.0% and 26.3% among the patients with Stage I, II, III
and IV disease, respectively. The rate of an EMT-positive
status among the patients with advanced cancer (Stage II,
III, IV) had a tendency to be higher than that observed
among the patients with early-stage cancer (Stage I). There
were no significant associations between the rate of an
EMT-positive status and the histological subtype. The rate
of an EMT-positive status was 16.4% in the patients with a
positive peritoneal cytology, in comparison to 27.5% in the
patients with a negative peritoneal cytology. These rates
Table 2 EMT status
Variables EMT status (n = 174)
Positive (%) Negative (%) p-value
Age 0.41
< 50 11 (22.9) 37 (77.1)
≥ 50 22 (17.5) 104 (82.5)
Histology 0.11
Serous 8 (16.7) 40 (83.3)
Mucinous 3 (14.3) 18 (85.7)
Clear 11 (34.4) 21 (65.6)
Endometrioid 2 (6.2) 30 (93.8)
SSPC 6 (23.1) 20 (76.9)
Others 3 (20.0) 12 (80.0)
FIGO stage 0.38
I 7 (12.5) 49 (87.5)
II 4 (28.6) 10 (71.4)
III 17 (20.0) 68 (80.0)
IV 5 (26.3) 14 (73.7)
Lymph node metastasis 0.15
Positive 9 (27.3) 24 (72.7)
Negative 12 (13.5) 77 (86.5)
Nx* 12 (23.1) 40 (76.9)
peritoneal cytology 0.12
Positive 22 (16.4) 112 (83.6)
Negative 11 (27.5) 29 (72.5)
Peritoneal metastasis <0.05
Positive 24 (25.5) 70 (74.5)
Negative 9 (11.3) 71 (88.7)
*Nx: no lymphadenectomy.
Table 3 Comparison of the primary and disseminated
tumors
Variables Primary tumor Disseminated tumor
n = 34 (%) n = 34 (%) P-value
E-cadherin 0.47
Reduced 16 (47.1) 19 (55.9)
Preserved 18 (52.9) 15 (44.1)
Snail 0.32
Positive 11 (32.4) 15 (44.1)
Negative 23 (67.6) 19 (55.9)
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negative patients, respectively. There were no significant
associations between the rate of an EMT-positive status
and the peritoneal cytology or presence of lymph node
metastasis. However, the rate of an EMT-positive status
was significantly higher in the patients with peritoneal
metastasis than in those without (p < 0.05).Correlation between the EMT status of the primary
tumor and the presence of any corresponding
metastases
Forty specimens of primary tumors and corresponding
metastases (13 lymph node metastases and 34 peritoneal
metastases) of epithelial ovarian cancer were examined
regarding the EMT status. The results are shown in
Table 3. No associations were observed between the data
for the primary tumors and those of the corresponding
metastatic sites. The rates of an EMT-positive status at
primary and metastatic sites were similar.Prognostic impact of the EMT status in patients with
endometrial carcinoma
The data for the EMT status were compared with the pa-
tient survival. The progression-free and overall survival
were stratified according to the EMT status using the
Kaplan-Meier method with the log-rank test (Figure 2).
The EMT status was found to be significantly associated
with both the progression-free survival (p < 0.05) and
overall survival (p <0.01). A multivariate analysis using a
Cox proportional hazards model was conducted to assess
the predictive value of the tumor EMT status (Table 4). The
analysis included the following prognostic variables: lymph
node metastasis (positive/negative), peritoneal cytology
(positive/negative) and peritoneal metastasis (positive/
negative). An EMT-positive status (95% CI, 1.16–7.53;
p <0.05) along with the presence of lymph node metastasis
(95% CI, 2.15-12.8; p <0.01), the peritoneal cytology (95%
CI, 1.31-8.93; p <0.05) and presence of peritoneal metasta-
sis (95% CI, 1.01-4.89; p <0.05), were identified to be signifi-
cant predictors of overall survival.
Discussion
The current study revealed the presence of active, that
is, localized in the nucleus, Snail proteins and their tar-
get E-cadherin on immunohistochemistry in a series of
primary ovarian carcinomas and corresponding metasta-
ses. Malignant epithelial tumors can invade surrounding
tissues via a variety of mechanisms [34]. The EMT is con-
sidered to be an important means of achieving tumor inva-
sion and metastasis in many common cancers. The current
study is the first report to demonstrate that the EMT status,
as represented by both a reduced E-cadherin expression
and the presence of a nuclear Snail expression, is an inde-
pendent predictive factor of patient survival in the setting
of ovarian cancer. Although we also evaluated the Slug
status, including the expression of other Snail-related zinc-
finger transcription factors, and the vimentin status, a
mesenchymal marker, in the tissue microarray samples, the
nuclear expression of Slug was observed in only 14.4% of
the primary tumors, with no substantial differences in
terms of the clinical relevance and/or prognostic impact. In
Figure 2 Survival curves for the 174 ovarian cancer patients generated according to the Kaplan-Meier method. The progression-free and
overall survival rates of the patients were stratified according to the EMT status. The EMT status, as represented by both a reduced E-cadherin
expression and the presence of a nuclear Snail expression, was defined as positive. The P-values were calculated using the log-rank test.
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of the primary tumors, with no substantial differences in
clinical relevance or prognostic impact. Therefore, we be-
lieve that the Slug and vimentin expression levels should be
excluded as markers of the EMT status in the current study
(Additional file 1: Table S1 and Additional file 2: Table S2).
We evaluated the presence of a reduced E-cadherin expres-
sion in the tissue microarray samples. The cell adhesion
molecule E-cadherin has previously been described to be
involved in tumor dedifferentiation and associated with a
poor recurrence-free survival [35,36]. A key regulator of the
E-cadherin expression in the zinc-finger transcription factor
Snail, a master regulatory molecule of the EMT [28]. Al-
though we also evaluated the presence of a nuclear Snail
expression in the tissue microarray samples, the rate of a
nuclear Snail expression showed no substantial differences
with respect to the FIGO stage or the histological subtype
and was not found to be associated with the peritoneal cy-
tology, presence of lymph node metastasis or peritoneal
dissemination or overall survival. These results are very
similar to those described in a previous report [33].
Blechschmidt et al. reported that the presence of a Snail ex-
pression in metastases of ovarian cancer is significantly as-
sociated with a lower overall patient survival, although the
Snail expression was not found to be associated with clini-
copathological parameters or the overall survival [33].Table 4 Multivariate analysis of prognostic factors
Risk Odds ratio 95% CI* p-value
Lymph node metastasis 5.14 2.15-12.8 <0.01
peritoneal cytology 3.25 1.31-8.93 <0.05
Peritoneal metastasis 2.19 1.01-4.89 <0.05
EMT status 2.90 1.16-7.53 <0.05
*CI: confidence interval.In the current study, we demonstrated the EMT status
to be significantly associated with peritoneal metastasis
and both progression-free (p < 0.05) and overall (p <
0.01) survival. However, there were no correlations be-
tween the presence of a Snail expression and a reduced
E-cadherin expression in either the primary tumors or
corresponding metastatic tumors, thus suggesting that
immunohistochemistry cannot be used to directly dem-
onstrate the status of invasive malignant cells. However,
the EMT status, as well as the rates of a reduced
E-cadherin expression and the presence of a nuclear ex-
pression of Snail in the primary and metastatic tumors,
were similar. In the current study, the data for the
EMT status, which was represented by both a reduced
E-cadherin expression and the presence of a nuclear Snail
expression in the ovarian cancer specimens, indicated that
the EMT appears to promote the dissemination of cells
from the tumor mass [37] and that cells undergoing the
EMT become invasive and develop resistance to anticancer
agents [38,39]. The EMT can induce resistance to multiple
drugs, permitting rapid tumor progression. The molecular
mechanisms underlying the process of the EMT in
cancer progression and metastasis, in which cells de-
tach from the primary tumor and invade the surround-
ing tumor stroma, are not well understood, and we
were unable to clarify these mechanisms in the present
study. Further in vitro examinations are therefore re-
quired to clarify whether Snail regulates the invasive-
ness and metastasis of cancer cells in patients with
ovarian cancer.
In conclusion, the current study demonstrated the EMT
status, as represented by both a reduced E-cadherin
expression and the presence of a nuclear Snail expression,
to be an independent predictor in patients with ovarian
cancer. These results indicate that E-cadherin and
Snail are potentially useful molecular targets in ovarian
cancer.
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